Whole Exome Sequence Of BON-1 And QGP-1, Two Human Pancreatic Neuroendocrine Tumor Cell Lines, Reveals Homozygous Loss Of Function Mutations In TP53, HRNR and CYFIP2. Abstract #775

Introduction: The human BON-1 and QGP-1 cell lines are two models often used in pancreatic neuroendocrine tumor (PNET) research. Data on protein-changing mutations in these cell lines is lacking.
Aim(s):
Materials and methods: Using the HiSeq 1000 next-generation DNA sequencing platform (Illumina), we sequenced the exome of the QGP-1 and BON-1 cell lines. Exonic sequences were enriched using the Truseq Exome Enrichment Kit (Illumina). Paired-end reads were aligned to the human reference genome. Single Nucleotide Variants (SNVs) and indels were called using the Genome Analysis ToolKit.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Timon Vandamme

To read results and conclusion, please login ...

Further abstracts you may be interested in

#977 Inducing, Understanding and Overcoming Resistance to Everolimus in Pancreatic Neuroendocrine Tumors
Introduction: Treatment with the mTOR-inhibitor everolimus improves progression-free survival in advanced pancreatic neuroendocrine tumors (PNETs). However, adaptive resistance to mTOR inhibition is described.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Timon Vandamme
Keywords: everolimus
#374 Hyperammonemic Encephalopathy in Neuroendocrine Tumor Resolved Through Liver Embolization: A Case Report
Introduction: Gastroenteropancreatic neuroendocrine tumors are a rare cause of secondary hyperammonemic encephalopathy. Possible etiological mechanisms are global hepatic dysfunction secondary to tumor burden or microvascular portosystemic shunting in the liver metastases often present in GEP-NET.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Timon Vandamme
Authors: Vandamme T, Kunnen J, Simoens M, ...
#1461 Whole Exome Sequencing of Three Families with Small Intestine Neuroendocrine Tumors
Introduction: Small intestine neuroendocrine tumors (siNETs) are the most prevalent small intestine neoplasms. However, familial siNETs are rarely described.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Matthias Beyens
#1543 Is True Non-Secretion of Chromogranin A an Unfavorable Prognostic Factor in Patients with ENETs TNM Stage IV Gastroenteropancreatic Neuroendocrine Tumors?
Introduction: Chromogranin A (CgA) is the best available serum marker for the work-up of gastroenteropancreatic NETs (GEP-NETs) and correlates with tumor volume & biological activity. During diagnosis & follow-up we found patients with elevated CgA levels and patients without elevated CgA levels (=‘true non-secretors’). We postulated that lack of secretion is a sign of dedifferentiation with a poorer prognosis.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Biomarkers
Presenting Author: drs. Kimberly Kamp
Keywords: GEP-NET, CgA, prognosis
#1895 Prospective Study on the Impact of a Multi-Institutional NET-Specific Multidisciplinary Tumor Board on Individual Treatment Plans
Introduction: A multi-institutional health network (nine hospitals) was set up in the Belgian Antwerp-Waasland region for the multidisciplinary care of gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients, called “NETwerk”. Local multidisciplinary teams refer all GEP-NET patients to be discussed among specialists, experienced in NET diagnostics and treatment, at a NET specific multidisciplinary tumorboard (MDT).
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Prof. Marc Peeters